Skip to main content
. 2022 Oct 3;10(1):234–244. doi: 10.1002/ehf2.14173

Table 2.

Diagnostic characteristics of patients with confirmed ATTRwt

Patient Amyloid type Age, years Gender (M/F) Years since CTS History of spinal stenosis Kappa, mg/L Lambda, mg/L K/L ratio Monoclonal spike band DPD Perugini grade Myocardial biopsy
#1 ATTRwt 71 M 5.6 No 26.3 15.1 1.75 No 3 No
#2 ATTRwt 71 M 5.4 No 13.3 15.7 0.85 No 3 No
#3 ATTRwt 90 M 4.7 No 12.7 12.1 1.05 No 2 Yes
#4 ATTRwt 87 M 4.7 No 23.3 19.9 1.17 No 2 No
#5 ATTRwt 69 M 3.7 No 22.5 18.0 1.25 No 3 Yes
#6 ATTRwt 83 M 2.9 No 27.7 11.2 2.47 No 3 Yes
#7 ATTRwt 84 M 2.9 No 35.2 30.0 1.17 Yes 3 Yes
#8 ATTRwt 87 F 2.7 Yes 22.3 14.4 1.55 No 3 No
#9 ATTRwt 85 M 6.5 No 20.0 18.6 1.08 No 3 Yes
#10 ATTRwt 79 M 2.9 No 45.8 6.6 7.0 Yes 2 Yes

ATTRwt, wild‐type transthyretin cardiac amyloidosis; CTS, carpal tunnel syndrome; DPD, technetium‐99m 3,3‐diphosphono‐1,2‐propanodicarboxylic acid scintigraphy.